Methamphetamine: Legislation and Issues in the 110th Congress

Methamphetamine: Legislation and Issues in the 110th Congress

Order Code RS22325
Updated October 23, 2008
Methamphetamine: Legislation and Issues
in the 110th Congress
Celinda Franco
Specialist in Social Legislation
Domestic Social Policy Division
Summary
Illicit methamphetamine (MA) production and use are longstanding and severe
problems in some states. In recent years, concerns were raised that this drug problem
was spreading nationwide, and MA issues became an important federal concern. During
the 110th Congress, legislation was introduced on a broad range of issues related to MA
abuse, illicit manufacture, treatment, and drug trafficking offenses. For example, S.
1276, the Methamphetamine Production Prevention Act of 2008 (P.L. 110-415), further
specified the procedures retailers must follow for tracking the retail purchases of over-
the-counter (OTC) medications containing MA precursor chemicals. H.R. 1199, the
Drug-Endangered Children Act of 2007 (P.L. 110-345), extended the authority of the
Drug-Endangered Children grant program through FY2009. Some of the MA legislation
would have built on provisions enacted in the Combat Methamphetamine Epidemic Act
(CMEA, P.L. 109-177), which were designed to control and limit the availability of MA
and its precursor chemicals. MA abuse has implications for public health, child welfare,
crime and public safety, and international relations. This report provides a brief
overview of MA abuse, its illicit domestic manufacture, federal responses, and anti-MA
legislation introduced in the 110th Congress. This report has been updated to reflect
legislative activity.
Background
Methamphetamine (MA), a drug of the amphetamine group, is a powerful and
addictive central nervous system stimulant. Originally used as a nasal decongestant and
bronchiodialator, MA has been marketed under the trade names Methedrine® and
Desoxyn® since the 1940s. MA is currently used to treat a limited number of medical
conditions, including narcolepsy, attention deficit disorder/attention deficit/hyperactivity
disorder (ADD/ADHD), and obesity. MA can be administered orally, nasally, by
injection, and, in the powder form that resembles granulated crystals, often referred to as

CRS-2
“ice,” by smoking.1 MA use can cause convulsions, stroke, cardiac arrhythmia, and
hyperthermia. Chronic use can lead to irreversible brain and heart damage, psychotic
behavior including paranoid ideation, visual and auditory hallucinations, rages and
violence. Withdrawal from MA can induce long-term depression, anxiety, and fatigue.

Illicit MA manufacture and abuse are longstanding and severe problems in some
states and regions of the country, particularly in the West, Midwest, and Southeast. Over
the past 30 years, Congress has passed legislation designed to address the problem of
illicit MA abuse and its manufacture in clandestine labs, including legislation to regulate
MA precursor chemicals, enhance penalties for drug trafficking, and increase funding for
MA-specific law enforcement programs. Congress continues to be concerned about the
abuse and illicit manufacture of MA.
According to the 2007 National Survey on Drug Use and Health (NSDUH), there
were approximately 529,000 current users of MA aged 12 or older (0.2% of the
population), compared with the 2006 estimate of 731,000 current MA users (0.3% of the
populations).2 Reported MA use among young adults aged 18 to 25 decreased from 0.6%
to 0.4% between 2006 and 2007. Table 1 provides the latest NSDUH data available on
the number of past-month MA users who met the criteria for illicit drug dependence or
abuse. The number MA users reporting dependence or abuse increased from 250,000
users in 2003 to 257,000 in 2005, although there was a marked spike in the number
reporting dependence or abuse of MA in 2004. Of those persons reporting dependent use
in the last month in 2005, 103,000, or 20%, reported using stimulants (most often MA)
as their primary substance of abuse.
Table 1. Use of MA Among Persons Aged 12 or Older, 2003-2006
(in thousands)
Use
2003
2004
2005
2006
Lifetime Use
15,139
14,512
12,663
14,206
Use in Last Year
1,602
1,808
1,603
1,889
New Users in Last Year
260
318
192
259
Use in Past Month
726
706
628
731
Dependent Use in Last Month
250
346
257
N/A
Stimulant is Primary Drug of Abuse
92
130
103
N/A
Other Illicit Drug is Primary Drug of Abuse
158
216
154
N/A
Source: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services
Administration, Office of Applied Studies, National Survey of Drug Use and Health, 2003-2006.
Sources of Illicit Methamphetamine
According to the Drug Enforcement Agency (DEA), most illicit MA available in the
United States is produced in laboratories located in Mexico or California, which is then
1 U.S. Department of Justice, Drug Enforcement Agency, Methamphetamine and Amphetamines,
Fact Sheet, at [http://www.dea.gov/concern/meth_factsheet.html].
2 U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services
Administration, Office of Applied Statistics, 2007 National Survey on Drug Use and Health
Report, September 4, 2008.

CRS-3
distributed across the country using existing drug trafficking routes. DEA estimates that
around 80% of all MA consumed in the United States is smuggled into the country from
Mexico.3
Clandestine “Super” Laboratories. As noted above, most illicit MA available
in the United States is produced in large clandestine laboratories in Mexico and
California.4 In these large labs, known as “super labs,”5 MA is produced by persons
linked to established drug trafficking organizations (DTOs). These super labs most often
obtain the precursor chemicals they need to manufacture illicit MA in wholesale
quantities on the international market. According to DEA, much of the MA precursor
chemical, pseudoephedrine, is either purchased by DTOs from one of seven chemical
companies in Europe, Asia, and the Far East and smuggled into Mexico and the United
States, or diverted from legitimate sources.
Small Clandestine Labs. The small domestic amateur labs, commonly referred
to as “box” or “mom-and-pop” labs, can be set up in home kitchens, motel rooms, or other
similar spaces, and produce MA with pseudoephedrine and other ingredients available at
retail stores. These small labs produce illicit MA using one of several relatively simple
methods that are readily available on the Internet and other sources. The methods most
commonly used to manufacture MA in amateur labs rely on the precursor chemicals,
ephedrine, pseudoephedrine, or phenylpropanolamine, which are commonly found in
over-the-counter (OTC) cold and sinus medicines available from any drug store.6 In
combination with common household and agricultural products, such as acetone,
hydrochloric acid, sodium hydroxide, ether, anhydrous ammonia, cat litter, antifreeze, and
drain cleaner, precursor chemicals are synthesized into MA.
Federal Enforcement Programs7
Many agencies and bureaus within DOJ are involved in addressing the issue of illicit
MA. Chief among them is the DEA. Through collaborations with the Federal Bureau of
Investigation (FBI), and numerous task forces, including the Organized Crime Drug
Enforcement Task Force (OCDETF) and the High Intensity Drug Trafficking Areas
(HIDTA), and collaborations with other federal, state, and local law enforcement, DEA
targets drug traffickers across the country and internationally to stem the flow of illegal
3 Ibid.
4 U.S. DOJ, DEA, Methamphetamine Brief, available online at [http://www.usdoj.gov/dea/
concern/meth_factsheet.html].
5 A “super lab” is one that is capable of producing 10 pounds or more of MA per production
cycle.
6 For example, pseudoephedrine is an active ingredient in products like Sudafed, Actifed, NyQuil,
and Claritin-D.
7 Other federal programs providing prevention and treatment of MA use, and assisting localities
with clandestine lab remediation, are beyond the scope of this report.

CRS-4
drugs in the United States. According to DEA, the total amount of MA interdicted at the
U.S.-Mexico border in 2002 had increased by more than 17% since 1999.8
The “Meth Hot Spots” program under the Community Oriented Policing Services
(COPS)9 program is a grant program that specifically provides funding for a broad range
of initiatives designed to assist state and local law enforcement in undertaking anti-MA
initiatives. Between 1998 and 2007, the COPS program has provided more than $448
million nationwide to address the MA problem.10 For FY2007, approximately $47
million was available for COPS Methamphetamine initiative.11 The Consolidated
Appropriations Act, 2008 (P.L. 110-161), included funding of almost $61.2 million for
the Meth Hot Spots program.12
The Combat Methamphetamine Epidemic Act (P.L. 109-177)
During the 109th Congress, passage of the USA PATRIOT Improvement and
Reauthorization Act of 2005, included Title VII, the Combat Methamphetamine Epidemic
Act (P.L. 109-177), legislation designed to curb MA use, trafficking, and production.
Signed into law on March 9, 2006, Title VII of P.L. 109-177 included provisions to limit
the diversion of MA precursor chemicals, domestically and internationally, increase MA-
related criminal penalties, expand measures related to illicit MA laboratory clean up, and
create a grant program to prevent and treat MA abuse among parenting women. The law

! limits OTC retail purchases of cold and sinus medications containing
MA-precursor chemicals13 to 3.6 grams a day; limits mail order purchases
of similar OTC medications to 7.5 grams a month;
! requires that retailers of OTC medications containing MA-precursors be
kept behind the counter, and that purchasers of more than 60 mg (two
dosage units) of pseudoephedrine must show a form of government-
issued photo identification and sign a registry for such purchases;
! requires that the Attorney General (AG) establish production and import
quotas for MA-precursor chemicals; impose criminal sanctions for
violations of these quotas; expands the AG’s authority to regulate
controlled substance imports;
! provides additional criminal penalty enhancements equal to a consecutive
term of up to 15 years imprisonment for individuals convicted of
8 DEA Resources, For Law Enforcement Officers, Intelligence Reports, Federal-Wide Drug
Seizures, available at [http://www.usdoj.gov/dea/].
9 For more information on the COPS program, see CRS Report RL33308, The Community
Oriented Policing Serives (COPS): Background, Legislation and Issues, by Nathan James.
10 U.S. Department of Justice, Office of Community Oriented Policing Services, COPS Fact
Sheet: Methamphetamine Initiative, August 2007, available at [http://www.cops.usdoj.gov].
11 Ibid.
12 Other DOJ grant programs under the Office of Justice Programs provide assistance for a broad
range of state and local law enforcement programs and initiatives which can include anti-MA
efforts.
13 MA precursors include pseudoephedrine, ephedrine, and phenylpropanolamine.

CRS-5
smuggling MA using dedicated commuter lanes at border crossings and
further makes such persons permanently ineligible from using such lanes;
a maximum fine of not less than $500,000 for manufacturing a controlled
substance on federal property; reductions in the threshold amounts of MA
required to trigger prosecution as an MA “drug kingpin”; additional term
of imprisonment of up to 20 years in cases where the manufacture or
trafficking in MA is carried out where children are present or reside;
! requires mandatory drug testing and sanctions for drug court participants
and authorizes appropriations of $70 million for drug court grants;
! reauthorizes the COPS Meth Hot Spots program, authorizing
appropriations of $99 million for each of the fiscal years 2006-2010;
! authorizes appropriations of $20 million for FY2006 and FY2007 for
grants to states for drug-endangered children programs; and
! authorizes such sums as may be necessary for a competitive grant
program for state, local, and tribal governments to provide services for
MA use by pregnant and parenting women offenders.
Legislation in the 110th Congress
Legislation to address the ongoing problem of illicit use and manufacture of MA was
considered and enacted during the 110th Congress. H.R. 1199, the Drug-Endangered
Children Act of 2007 (P.L. 110-345), passed by the House and Senate on September 24,
2008, extended the authority of the Drug-Endangered Children grant program through
FY2009. Four bills, S. 85, S. 267, H.R. 545, and S. 2087, would have clarified that
territories and Indian tribes were eligible to receive MA-related grants for drug-
endangered children and for addressing MA use by pregnant and parenting women
offenders provided under CMEA. These bills were not enacted, although Congress did
enact similar amendments under the Consolidated Appropriations Act, 2008 (P.L. 110-
161), to include territories and Indian tribes among those entities eligible to receive such
grants.
H.R. 405, S. 884, S. 1367, H.R. 3130, H.R. 3749, and H.R. 6901 would have
amended the Public Health Service Act to provide residential family treatment programs
for pregnant and parenting women, including treatment for MA addiction and MA
treatment alternatives to incarceration for non-violent offenders.14 H.R. 3186 and S. 1906
would have established a program to investigate oral health problems associated with MA
use, known as “meth mouth,” while H.R. 3187 and S. 1907 would have focused on
similar oral health problems among prison inmates. H.R. 3433 would have required a
survey of research on MA treatment and recommend additional research avenues.
H.R. 365 (P.L. 110-143) provided for a research program for remediation of
clandestine MA laboratories,15 similar to those included in S. 635. P.L. 110-143 also
provided for the establishment of voluntary guidelines for the remediation of MA
laboratory sites; established a research program to support the development, assessment,
14 For more information, see CRS Report RL33354, The Promoting Safe and Stable Families Act:
Reauthorization in the 109th Congress, by Emilie Stoltzfus.
15 For more information, see CRS Report RL32959, Methamphetamine Lab Clean-Up and
Remediation Issues, by Michael M. Simpson.

CRS-6
and revision of these guidelines; and authorized appropriations of $2.5 million to fund
research on the residual toxic effects of MA laboratories, and research on developing new
MA site detection technologies, such as field test kits and other methods of detecting
these toxic sites. H.R. 955 would have, among other things, authorized funding for
environmental cleanup of lands contaminated by hazardous substances associated with
the illicit manufacture of MA, and provided grants for state and local governments to
cleanup and dispose of hazardous MA by-products. S. 2100 would have required that
federal forfeiture funds be used, in part, to pay for MA laboratory cleanup.
S. 4, Improving America’s Security Act of 2007 (P.L. 110-53), included provisions
to establish a “Rural Policing Institute” as part of the Federal Law Enforcement Training
Center (based in Glynco, Georgia) where, among other things, programs for rural law
enforcement agencies would include training on addressing MA addiction and
distribution. H.R. 1028, S. 560, and H.R. 1697 included similar provisions. S. 368 and
H.R. 1700 would have amended the COPS program to authorize, among other things, the
AG to establish and implement innovative programs to reduce and prevent the illegal
manufacturing, distribution, and use of MA.
S. 132 would have lowered the threshold for possession of MA required to constitute
violation under current law (21 U.S.C. §848) and triggering prosecution as a “continuing
criminal enterprise,” as well as increasing penalties and fines for violations involving MA
or its salts, isomers, or salts of isomers. H.R. 3143 and S. 2137 would have lowered the
criminal thresholds for classifying an offender as an MA “kingpin” and increased the
penalty enhancements for such crimes, as well as establishing a multi-jurisdictional MA
task forces of federal, state, local law enforcement. H.R. 1118 would have enhanced
criminal penalties for drug trafficking offenses relating to the manufacture and
distribution of large amounts of MA. Similarly, H.R. 2425 would have enhanced
penalties for marketing MA and other drugs to minors, while S. 1211 would have
enhanced penalties for marketing all controlled substance to minors. H.R. 246 and S.
1178 would have required the AG to conduct a study evaluating whether there is a
connection between the commission of MA-related crimes and identity theft crimes.
S. 1276, the Methamphetamine Production Prevention Act of 2008 (P.L. 110-415),
as amended and passed by the Senate and the House on September 29, 2008, specified the
procedures and identification requirements for tracking the retail purchases of over-the-
counter (OTC) medications containing MA precursor chemicals. S. 1276 required that
retailers obtain and record identifying information from prospective purchasers of certain
types of OTC medications, further specified how paper or electronic signatures are to be
collected, and required that retailers retain this information for at least two years. H.R.
2747 and S. 2237 also would have established a grant program to support the use of
electronic logbooks for collecting and maintaining records of MA-precursor transactions
to aid in the control of MA precursor chemicals. S. 2071 and H.R. 5619 would have
required the self-certification of all “persons” selling MA precursor chemicals from
behind the counter in retail stores.